Journal
ADVANCED MATERIALS
Volume 31, Issue 19, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.201805697
Keywords
blood-brain barrier; brain tumors; central nervous system diseases; monoclonal antibodies; nanomedicine
Categories
Funding
- National Key Research and Development Programs of China [2016YFC0902502, 2018YFA0209700]
- National Nature Science Foundation of China [51773151, 81602208]
- Postdoctoral Science Foundation of China [2015M580212]
Ask authors/readers for more resources
As an essential component of immunotherapy, monoclonal antibodies (mAbs) have emerged as a class of powerful therapeutics for treatment of a broad range of diseases. For central nervous system (CNS) diseases, however, the efficacy remains limited due to their inability to enter the CNS. A platform technology is reported here that enables effective delivery of mAbs to the CNS for brain tumor therapy. This is achieved by encapsulating the mAbs within nanocapsules that contain choline and acetylcholine analogues; such analogues facilitate the penetration of the nanocapsules through the brain-blood barrier and the delivery of mAbs to tumor sites. This platform technology uncages the therapeutic power of mAbs for various CNS diseases that remain poorly treated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available